DDInter833 DDInter625
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Elagolix
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Fentanyl
Fentanyl {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Abdominal pain upper {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Glycerol phenylbutyrate (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may lead to a major life threatening interaction when taken with Elagolix
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Fentanyl (Compound) and Fentanyl may lead to a major life threatening interaction when taken with Elagolix
Glycerol phenylbutyrate (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Elagolix